Literature Highlights

Each week, the main highlight from a new Covid-19 research article will be summarized in an infographic. Please come back weekly for more infographic highlights covering diagnosis, risk factors, treatment, and more.

  • Interim Results of a Phase 1-2a Trial of Ad26.COV2.S COVID-19 Vaccine

  • Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19

  • Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Trial

  • REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19

  • Pre-pandemic Psychiatric Disorders and Risk of COVID-19: A UK Biobank Cohort Analysis

  • Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact

  • SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19

  • Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates

  • Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

  • Therapeutic Versus Prophylactic Anticoagulation for Severe COVID-19: A Randomized Phase II Clinical Trial (HESACOVID)

  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

  • Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

  • Effects of COVID-19 on the Nervous System

  • COVID-19 Vaccine: A Comprehensive Status Report

  • Extrapulmonary Manifestations of COVID-19

  • Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of SARS-CoV-2 and COVID-19: A Systematic Review and Meta-Analysis

  • Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report

  • Safety and Immunogenicity of the ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-19: A Preliminary Report of a Phase 1/2, Single-Blind, Randomized Controlled Trial

  • An mRNA vaccine Aganist SARS-CoV-2 – Preliminary Report

  • Triple Combination of Interferon Beta-1b, Lopinavir-Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial

  • Pilot Prospective Open, Single-arm Multicentre Study on Off-label Use of Tocilizumab in Patients With Severe COVID-19

  • Observational Study of Hydroxychlaraquine in Hospitalized Patients with COVID-19

  • Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections

  • Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital

  • Biomarkers Associated with COVID-19 Disease Progression

  • Remdesivir for the Treatment of COVID-19 – Preliminary Report

  • A Comparative Study on the Clinical Features of COVID-19 Pneumonia to Other Pneumonias

  • Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

  • Candidate drugs against SARS-CoV-2 and COVID-19

Copyright © 2020 | COVID Frontline | All Rights Reserved | Website by Divigner

Patient Toolkit

The COVID FRONTLINE Patient Toolkit is a resource center for patients who have been diagnosed with or who are interested in learning about COVID-19. Choose from the options below to learn more.

Clinical Toolkit

The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Merck & Co., Inc., and Pfizer.

Copyright © 2019 | COVID Frontline | All Rights Reserved | Website by Divigner

Updates in the Treatment and Prevention of COVID-19​

Emergency use authorization for casirivimab/imdevimab in patients with mild-to-moderate COVID-19

The combination of the monoclonal antibodies casirivimab and imdevimab (previously known as REGN-COV2) has been authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (≥12 years of age and ≥40 kg) who are at high risk for progressing to severe COVID-19 or hospitalization.1

Interim results from 275 nonhospitalized patients in a placebo-controlled trial of casirivimab plus imdevimab found that the combination therapy reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Patients who received casirivimab/imdevimab required fewer medical visits for COVID-19 than patients who received placebo (3% vs 6%, respectively). Among patients who were serum antibody-negative at baseline, 15% in the placebo group and 6% in the treatment group required COVID-19-related medical care.2

Baricitinib in combination with remdesivir authorized for emergency use in hospitalized patients

Baricitinib, in combination with remdesivir, is authorized for emergency use in adult and pediatric patients ≥2 years of age hospitalized for COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).3

A recent trial of 1033 patients hospitalized for COVID-19 found that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time (7 days vs 8 days, respectively; P= .03). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination therapy and 18 days with the control (rate ratio for recovery, 1.51). The addition of baricitinib to remdesivir was associated with 30% higher odds of improvement in clinical status at day 15 compared with remdesivir alone.4

 

References 

  1. Emergency use authorization (EUA) of casirivimab and imdevimab. Available at fda.gov/media/143892/download Accessed 12/23/2020.
  2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020;Dec 17:Epub ahead of print. Available at nejm.org/doi/full/10.1056/NEJMoa2035002Accessed 12/23/2020.
  3. Emergency use authorization (EUA) of baricitinib. Available at fda.gov/media/143823/download Accessed 12/23/2020.
  4. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020;Dec 11:Epub ahead of print. Available at nejm.org/doi/full/10.1056/NEJMoa2031994 Accessed 12/23/2020.